Genmab (GMAB DC) H1 2026 (USD): EBIT 555mln, sees FY gross profit of 4.015-4.195bln

Interim prints of this kind from large-cap biotech names tend to be traded less on the reported half itself than on the guidance line, and here the FY gross profit range is the operative number: whether the band tightens, shifts, or simply reconfirms prior messaging is what typically re-prices the shares in the European session. A two-sided range of that width leaves room for the street to anchor at its midpoint and treat anything shy of prior consensus within it as a de facto cut, a pattern seen repeatedly with this peer set where pipeline-heavy revenue makes top-line visibility poor. The distinction worth drawing is between an EBIT beat driven by cost timing and one driven by royalty or collaboration income, since the former is routinely faded and the latter reads through to the durability of partnered-product cash flows. Follow-ons that have mattered in comparable episodes are the call commentary on partner-driven sales trends, any FX assumption embedded in the guidance given the USD reporting basis, and read-across to the royalty counterparty's own numbers. As an interims print rather than a full-year event, positioning adjustments have historically been modest unless the guidance band itself moves.